Free Trial

Dougherty & Co's Rating of HemaCare on 11/28/2018

On November 28, 2018, Dougherty & Co updated its outlook on HemaCare (OTCMKTS:HEMA) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Dougherty & Co

DateCompanyAction
6/7/2020
InterDigital, Inc. stock logo
IDCC
InterDigital
Reiterated Rating
5/27/2020
SWK Holdings Corp. stock logo
SWKH
SWK
Reiterated Rating
5/27/2020
Myomo, Inc. stock logo
MYO
Myomo
Reiterated Rating
5/28/2020
Workhorse Group, Inc. stock logo
WKHS
Workhorse Group
Initiated Coverage
5/27/2020
Myomo, Inc. stock logo
MYO
Myomo
Initiated Coverage
5/27/2020
SWK Holdings Corp. stock logo
SWKH
SWK
Initiated Coverage
More Ratings From Dougherty & Co